What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To assess the renal and hematologic efficacy and safety of a combination therapy for newly diagnosed multiple myeloma patients with severe renal impairment.

December 8, 2025BloodOpen Access

Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group

View Full Paper

Ask AI

Bookmark

Authors

VLVasiliki LampropoulouUniversity of Patras INIoannis Ntanasis-StathopoulosNational and Kapodistrian University of Athens MGMaria GavriatopoulouNational and Kapodistrian University of Athens

Discussion

Member takes

Overview

Phase 2 study shows improved progression-free survival and safety using Isatuximab with dexamethasone in multiple myeloma patients with renal issues.

Key Points

To assess the renal and hematologic efficacy and safety of a combination therapy for newly diagnosed multiple myeloma patients with severe renal impairment.
Phase 2, multicenter, open-label study
Patients received isatuximab with bortezomib, cyclophosphamide, and dexamethasone, followed by maintenance with isatuximab and lenalidomide
Endpoints included renal response rate, overall response rate, progression-free survival, overall survival, and safety.
Among 51 patients, 36 (72.0%) achieved at least a minor renal response in a median of 1.1 months
Progression-free survival was 77.6% at 12 months and 60.3% at 24 months
Overall survival was 82.96% at 12 months and 63.58% at 24 months

Cite This Study

Lampropoulou et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da87 https://doi.org/10.1182/blood-2025-4036

View Full Paper

Ask AI

Bookmark

Overview

Phase 2 study shows improved progression-free survival and safety using Isatuximab with dexamethasone in multiple myeloma patients with renal issues.

Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group

Discussion

Member takes

Overview

Key Points

Cite This Study

Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group

Discussion

Member takes

Overview

Key Points

Cite This Study

Also Consider

Also Consider